Virax Biolabs GroupVRAX -0.64%37 Quick Ratio is 11.22 as of Sep. 2025, which is 57% above its 10-year median of 7.13. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Virax Biolabs Group ranks better than 81.12% on this metric.
Virax Biolabs Group has a quick ratio of 11.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for Virax Biolabs Group's Quick Ratio or its related term are showing as below:
VRAX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 7.13 Max: 25.56
Current: 11.22
During the past 6 years, Virax Biolabs Group's highest Quick Ratio was 25.56. The lowest was 0.02. And the median was 7.13.
VRAX's Quick Ratio is ranked better than 81.12% of 1409
companies
in the Biotechnology industry
Industry Median: 3.6
vs VRAX: 11.22
Virax Biolabs Group (NAS:VRAX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Virax Biolabs Group Quick Ratio Related Terms
Virax Biolabs Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Virax Biolabs Group's Quick Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Quick Ratio of 11.22 as of Sep. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Virax Biolabs Group and its competitors. This is 57% above median its historical median of 7.13. Over the past decade, Virax Biolabs Group's Quick Ratio has ranged from 0.02 to 25.56. According to the industry distribution chart, Virax Biolabs Group ranks #266 out of 1409 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Virax Biolabs Group's Quick Ratio too high?
Virax Biolabs Group's current Quick Ratio of 11.22 is 57% above median its 10-year median of 7.13. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 25.56. The Biotechnology industry median Quick Ratio is 3.60. Virax Biolabs Group's value of 11.22 is 211.7% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #266 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Quick Ratio compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #266 out of 1409 companies for Quick Ratio. This places Virax Biolabs Group in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Virax Biolabs Group's value of 11.22 is 211.7% above this benchmark. Historically, Virax Biolabs Group's own Quick Ratio has ranged from 0.02 to 25.56 over the past decade. While the company's 10-year median is 7.13 vs. the industry median of 3.60, Virax Biolabs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Quick Ratio of 11.22 is 211.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Quick Ratio is 11.22, which is 57% above median its own 10-year median of 7.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Quick Ratio is 11.22, which is 57% above median its 10-year median of 7.13 and 211.7% above the Biotechnology industry median of 3.60. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Quick Ratio is 11.22 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Quick Ratio: 11.22 (57% above median its 10-year median of 7.13)
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
Industry Position: 211.7% above the Biotechnology median (#266 of 1409)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
